Risk Factors Update Summary

• Increased inflationary pressures, primarily in personnel costs and lab supplies, may impact costs.
• Revenue from patients derived from a commercial payor increased from 12% to 14%.
• Revenue exceeded $100.0 million for the year ended December 31, 2022, and market value exceeded $250.0 million.
• Net loss decreased from $67 million to $57 million, with an accumulated deficit increasing from $160 million to $218 million.
• The company will no longer qualify as a smaller reporting company, affecting reporting requirements.
• Number of issued U.S. patents increased from 15 to 16, with pending U.S. patent applications increasing from ten to 13.
• Medicare reimbursement rate for the IDgenetix multi-gene panel decreased from approximately $1,500 to $917 per test.
• Federal NOL carryforwards decreased from approximately $207 million to $197 million, with state NOL carryforwards decreasing from $114 million to $3 million.
• The company paused accepting TissueCypher orders temporarily in July 2023 to focus on scaling efforts.
• The company resumed accepting new TissueCypher orders in September 2023 after working through a significant backlog.